Clinical Trial - NCT02637531

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Recruiting

Sponsor: Infinity Pharmaceuticals, Inc.

Collaborators:

Information provided by (Responsible party): Sponsor

ClinicalTrials.gov Identifier: NCT02637531

Protocol Info

Short Description: Phase 1/1b IPI-549 w/ Nivolumab in Adv Solid Tumors
Long Description: A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors
MGH Status: Open
Sponsor: Infinity Pharmaceuticals
Disease Program: Phase I

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.




Purpose

This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
Condition Title Intervention Phase
Advanced Solid Tumors (Part A/B/C/D) Non-small Cell Lung Cancer (Part E) Melanoma (Part E) Squamous Cell Cancer of the Head and Neck (Part E) Triple Negative Breast Cancer (Part F) Adrenocortical Carcinoma (Part G) Mesothelioma (Part G) High-circulating Myeloid-derived Suppressor Cells (Part H) IPI-549 Nivolumab Phase 1
Study Type Interventional
Official Title A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Primary Outcome Measures

Part A/B/C: Dose Limiting Toxicities (DLT) [Time Frame: From date of initial dose until up to 28 days for IPI-549] [Designated as safety issue: ]

Part D/E: Adverse Events (AE) and safety laboratory values [Time Frame: Number of patients with Clinically significant abnormal laboratory values and adverse events that are related to treatment from date of initial dose until 30 days after last dose of IPI-549 and 100 days after the last dose of Nivolumab] [Designated as safety issue: ]


Secondary Outcome Measures

Part A/B: Adverse Events (AE) and safety laboratory values [Time Frame: Number of patients with Clinically significant abnormal laboratory values and adverse events that are related to treatment assessed during every visit for duration of study participation which is estimated to be 24 months] [Designated as safety issue: ]

Part A/B: Plasma concentrations of IPI-549 (metabolites, as appropriate) [Time Frame: Assessed during Days 1- 22 of Cycles 1 and 2, Assessed During Day 1 of Cycles 3 and 4] [Designated as safety issue: ]

Part A/B: Overall response rate (ORR), complete response/remission (CR) or partial response/remission (PR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part A/B: Duration of response (DoR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part C: Adverse Events (AE) and safety laboratory values [Time Frame: Number of patients with Clinically significant abnormal laboratory values and adverse events that are related to treatment assessed during every visit for duration of study participation which is estimated to be 24 months] [Designated as safety issue: ]

Part C: Plasma concentrations of IPI-549 (metabolites as appropriate) [Time Frame: Assessed during Days 1- 2 of Cycles 1 and 2] [Designated as safety issue: ]

Part C: Overall Response Rate (ORR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part C: Duration of Response (DoR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part D: Overall Response Rate (ORR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part D: Duration of Response (DoR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part D: Progression-Free Survival (PFS) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part D: Overall Survival (OS) [Time Frame: Estimated to be 3 years] [Designated as safety issue: ]

Part D: Plasma concentrations of IPI-549 (and metabolites, as appropriate) [Time Frame: Assessed during Days 1- 15 of Cycles 1 and 2, Assessed During Day 1 of Cycles 3 and 4] [Designated as safety issue: ]

Part E:Overall Response Rate (ORR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part F:Overall Response Rate (ORR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part G:Overall Response Rate (ORR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part E: Duration of Response (DoR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part F: Duration of Response (DoR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part G: Duration of Response (DoR) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part E: Progression Free Survival (PFS) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part F: Progression Free Survival (PFS) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part G: Progression Free Survival (PFS) [Time Frame: Responses Assessed in Cycle 3 and every odd cycle through study completion, an average of 1 year] [Designated as safety issue: ]

Part E: Overall Survival (OS) [Time Frame: Estimated to be 3 years] [Designated as safety issue: ]

Part F: Overall Survival (OS) [Time Frame: Estimated to be 3 years] [Designated as safety issue: ]

Part G: Overall Survival (OS) [Time Frame: Estimated to be 3 years] [Designated as safety issue: ]

Part E: Plasma concentrations of IPI-549 (and metabolites, as appropriate) [Time Frame: Assessed during Days 1- 2 of Cycles 1 and 2] [Designated as safety issue: ]

Part F: Plasma concentrations of IPI-549 (and metabolites, as appropriate) [Time Frame: Assessed during Days 1- 2 of Cycles 1 and 2] [Designated as safety issue: ]

Part G: Plasma concentrations of IPI-549 (and metabolites, as appropriate) [Time Frame: Assessed during Days 1- 2 of Cycles 1 and 2] [Designated as safety issue: ]

Estimated Enrollment: 220
Study Start Date: December 2015
Estimated Study Completion Date: September 2019
Estimated Primary Completion Date: June 2019
Arms Assigned Interventions

Experimental:Part A/B: IPI-549 Dose Escalation

Participants receive IPI-549 orally (PO) once a day (QD) for Part A and twice a day (BID) in Part B until disease progression.
Drug:IPI-549
IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Experimental:Part C: IPI-549 and nivolumab

Participants receive IPI-549 (dose determined from Part A/B) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
Drug:Nivolumab
Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).

Experimental:Part D: IPI-549 Monotherapy

Participants receive IPI-549 (dose determined from Part A/B) orally until disease progression.

Experimental:Part D Annex: IPI-549 and nivolumab

Participants receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.

Experimental:Part E: NSCLC: IPI-549 and nivolumab

Participants with NSCLC receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.

Experimental:Part E: Melanoma: IPI-549 and nivolumab

Participants with melanoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.

Experimental:Part E: SCCHN: IPI-549 and nivolumab

Participants with squamous cell cancer of the head and neck receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.

Experimental:Part F: TNBC: IPI-549 and nivolumab

Participants with triple negative breast cancer receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.

Experimental:Part G: ACC: IPI-549 and nivolumab

Participants with adrenocortical carcinoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.

Experimental:Part G: Mesothelioma: IPI-549 and nivolumab

Participants with mesothelioma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.

Experimental:Part H: High-circulating MDSCs: IPI-549 and nivolumab

Participants with high-circulating MDSCs receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.

Eligibility

Ages Eligible for Study: N/A-N/A

Genders Eligible for Study: All

Accepts Healthly Volunteers: No

Inclusion Criteria:

All subjects must meet the following criteria for inclusion:

  • ≥ 18 years of age
  • Life expectancy of ≥ 3 months
  • Histological or cytological evidence of advanced and/or metastatic carcinoma or melanoma , excluding sarcoma
  • At least 1 measurable disease lesion as defined by RECIST 1.1
  • Serum creatinine clearance ≥ 60 mL/min and serum creatinine ≤ 2.0 x the upper limit of normal (ULN) as determined by either of the following: Estimation as calculated by Cockcroft-Gault equation or Direct measurement by 24-hour urine collection
  • Total bilirubin ≤ 1.5 x ULN (unless elevated due to Gilbert's syndrome)
  • Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 x ULN (<5x ULN if liver metastasis)
  • Adequate hematological function, defined as absolute neutrophil count ≥1.5 x 109/L, hemoglobin ≥ 9.0 g/dL, and platelet count ≥ 100 x 109/L
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (corresponds to Karnofsky Performance Status (KPS) ≥ 60%)

Subjects entering Part A, B, C, or D must also meet the following additional criterion:

• Failure to respond to standard therapy, or for whom no appropriate therapies are available (based on the judgement of the Investigator)

Subjects entering Part D, E, F or G must also meet the following additional criterion:

• Willing to undergo 1 pre-treatment and 1 on-treatment tumor biopsy

Subjects entering Part E must also meet the following additional criteria:

  • Histological or cytological evidence of NSCLC, melanoma, , human papillomavirus (HPV) positive or HPV negative SCCHN (oral cavity, pharynx, hypopharynx, larynx, nasopharyngeal [including undifferentiated nasopharyngeal carcinoma]), or another tumor type to be determined
  • Failure to respond to standard therapy, or for whom no appropriate therapies are available (based on the judgment of the Investigator The most recent treatment prior to study entry must be an anti-PD-1 or anti-PD-L1 antibody given as either monotherapy or in combination
  • Subjects with NSCLC Tumors that harbor an actionable genetic alteration for which there is a corresponding approved therapy for that specific alteration (including but not limited to alterations in EGFR, ALK, and ROS) must have progressed on, or had intolerance to, the respective therapy

Subjects entering Part F must also meet the following additional criteria:

  • Histological or cytological evidence of estrogen-receptor negative (ER-), progesterone receptor negative (PgR-) and human epidermal growth factor-2 receptor negative (HER2-) Breast Cancer by local laboratory testing, based on last available tumor tissue; or another tumor type to be determined
  • ER/PgR negativity to follow local guidelines
  • If IHC HER2 2+, a negative FISH test is required
  • Inflammatory triple negative breast cancer is allowed
  • Must have received and failed/progressed a cytotoxic chemotherapy as first line therapy per standard of care
  • No prior anti-PD-1 or anti-PD-L1 therapy

Subjects entering Part G must also meet the following additional criteria:

  • Histological or cytological evidence of ACC, mesothelioma, or another tumor type to be determined
  • Both pleural and peritoneal mesothelioma are allowed
  • Epithelioid, sarcomatoid, or biphasic mesothelioma subtypes are allowed
  • Progression after at least first line available therapy

Patients entering Part H must also meet the following additional criteria:

High-circulating MDSCs, currently defined for this study as MDSCs

≥ 20.5% as measured by CLIA-certified Serametrix assay Microsatellite status of tumor has been determined Patients with tumors that are microsatellite instability-high must have previously received an anti-PD-1/anti-PD-L1 therapy and progressed on therapy If patient's tumor type is one for which anti-PD-1/anti-PD-L1 therapy is standard of care, patient must have previously received an anti-PD-1 or anti-PD-L1 therapy and progressed while on that therapy

Exclusion Criteria:

Subjects are to be excluded from the study if they meet any of the following criteria:

  • Severe allergic or anaphylactic reaction to any monoclonal antibody therapy, murine protein, or known hypersensitivity to any excipient in the study drugs
  • Major surgery within 4 weeks prior to Screening
  • Subjects who have been treated with chemotherapy, biologic therapy, or other investigational agent within < 5 times the half-life of the agent or < 28 days (whichever is shorter) of starting study drug

NOTE: Subjects whose immediate prior treatment was with nivolumab may start study drug 2 weeks after the last dose of nivolumab

  • Symptomatic or untreated brain metastases
  • Primary central nervous system (CNS) malignancy
  • Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus
  • Ongoing treatment with chronic immunosuppressants (eg, cyclosporine) or systemic steroids
  • Ongoing systemic bacterial, fungal, or viral infections at Screening

NOTE: Subjects on antimicrobial, antifungal, or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met

  • Administration of a live vaccine within 6 weeks of first dose of study drug
  • Administration of any of the following within 1 week prior to the administration of study drug:
  • Strong inhibitors or inducers of CYP3A4, including grapefruit products and herbal supplements
  • P-glycoprotein (P-gp) inhibitors
  • Warfarin, phenytoin, or other substrates of CYP2C8 or CYP2C9 with a narrow therapeutic range
  • Medications associated with QTc interval prolongation or Torsades de Pointes
  • Baseline QT interval corrected with Fridericia's method (QTcF) > 480 ms (average of triplicate readings) NOTE: criterion does not apply to subjects with a right or left bundle branch block
  • Parts C, D-Annex, and E only: Subjects with active, known, or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
  • Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
  • Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia
  • Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
  • History of peptic ulcer and/or gastrointestinal bleed
  • History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to Screening
  • Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the subject associated with his or her participation in the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT02637531

Locations

  • United States, California
    • UCSD San Diego, California, United States, 92093
    • UCLA Santa Monica, California, United States, 90404
  • United States, Florida
    • Hematology Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States, 34952
  • United States, Georgia
    • Emory University Atlanta, Georgia, United States, 30322
  • United States, Massachusetts
    • Massachusetts General Hospital Boston, Massachusetts, United States, 02116
    • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215
    • Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215
  • United States, New Jersey
    • Hackensack University Medical Center Hackensack, New Jersey, United States, 07601
  • United States, New York
    • Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065
  • United States, Texas
    • MD Anderson Cancer Center Houston, Texas, United States, 77030
    • South Texas Accelerated Research and Treatment (START) San Antonio, Texas, United States, 78229

Sponsors and Collaborators

Infinity Pharmaceuticals, Inc.

More Information

No publications provided

Responsible Party: Sponsor
ClinicalTrials.gov Identifier: NCT02637531
Other Study ID Numbers:
Study First Received:
Last Updated:
Health Authority:

Keywords provided by Infinity Pharmaceuticals, Inc.:

IPI-549

Phase 1

Advanced Solid Tumor

Non-small cell lung cancer

Melanoma

PI3K

Squamous Cell Cancer of the Head and Neck

Triple Negative Breast Cancer

Adrenocortical Carcinoma

Mesothelioma

High-circulating myeloid-derived suppressor cells (MDSCs)

Additional relevant MeSH terms:

Carcinoma, Non-Small-Cell Lung

Melanoma

Mesothelioma

Triple Negative Breast Neoplasms

Neoplasms, Squamous Cell

Carcinoma, Squamous Cell

Head and Neck Neoplasms

Adrenocortical Carcinoma

Nivolumab

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.







ClinicalTrials.gov processed this data on May 16, 2019